<DOC>
	<DOCNO>NCT00000941</DOCNO>
	<brief_summary>The purpose study find whether take protease inhibitor ( anti-HIV drug ) together lipid-lowering drug ( drug low amount fat blood ) effect level drug find blood compare drug take separately . The three protease inhibitor give study ritonavir , saquinavir , nelfinavir . The lipid-lowering drug give pravastatin , simvastatin , atorvastatin . Anti-HIV drug therapy use protease inhibitor become common treatment HIV-positive patient . Recently , however , serious side effect involve body use fat report people take protease inhibitor . Examples side effect redistribution body fat development diabetes . People take protease inhibitor find high level fat blood normal , cause heart problem . It hop give lipid-lowering drug help prevent serious heart problem . First , however , important see happen protease inhibitor lipid-lowering drug give together .</brief_summary>
	<brief_title>A Study Possible Interactions Between Protease Inhibitors ( Anti-HIV Drugs ) Drugs Which Lower Level Fat Your Blood</brief_title>
	<detailed_description>Potent antiretroviral therapy become standard care person HIV infection AIDS . Recently , however , number complication emerge widespread use protease inhibitor ( PI ) -based regimen , include : hyperlipidemia , hypertriglyceridemia , diabetes mellitus , lipodystrophy . Concern possibility premature myocardial infarction lead health care provider patient consider treat lipid metabolism disorder . Statin compound beneficial effect lipid-lowering agent , thereby reduce risk cardiovascular complication . Statin compound pravastatin , simvastatin , atorvastatin increasingly prescribed person take PI-based potent antiretroviral therapy . It important determine whether significant drug-drug interaction statin compound PIs . Fourteen healthy participant cohort Arm A stabilize fixed regimen pravastatin ( Arm A1 ) , simvastatin ( Arm A2 ) , atorvastatin ( Arm A3 ) 4 day . A baseline pharmacokinetic ( PK ) evaluation complete Day 4 . Pravastatin ( simvastatin atorvastatin ) dose stop follow Day 4 dose PK evaluation . On Day 5 , ritonavir saquinavir combination regimen initiate continued Day 18 study . Pravastatin ( simvastatin atorvastatin ) dose resume Day 15 continue Day 18 . A repeat PK evaluation pravastatin ( simvastatin atorvastatin ) context combination therapy carry Day 18 . Fourteen healthy participant assign Arm B ; participant begin 2-week regimen nelfinavir . On Day 14 , baseline PK profile nelfinavir M8 metabolite carry . Pravastatin add regimen Days 15 18 . On Day 18 , repeat PK evaluation nelfinavir M8 metabolite carry context combination therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVnegative . Are age 18 60 . Agree use barrier method birth control ( e.g. , condom ) study . Exclusion Criteria You eligible study : Have history chronic illness high blood pressure , heart disease , arthritis , diabetes . Are pregnant breastfeeding . Are take certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Interactions</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anticholesteremic Agents</keyword>
</DOC>